FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

The Best Red Light Therapy for Hair Growth

After 16 weeks of testing, we noticed visible results. Here are our favorite red light therapy devices for hair growth.

FDA Approves Novo Nordisk's Growth Disorder Treatment For New Populations

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.